U.S. Shingles Vaccine Approval Expanded

To include people in their 50s

THURSDAY, March 24 (HealthDay News) -- The Zostavax shingles vaccine is now approved by the U.S. Food and Drug Administration for people aged 50 and older.

FDA-sanctioned use of the vaccine, first approved in 2006, had been limited to people 60 and older. The expanded approval includes the approximately 200,000 people aged 50 to 59 who contract shingles each year, the agency said in a news release.

The vaccine was clinically evaluated in some 22,000 people aged 50 to 59. Zostavax reduced the risk of acquiring shingles by about 70 percent, compared to people who received an inactive placebo, the agency said.

Commonly reported side effects of the vaccine included injection-site redness, pain and swelling.

Zostavax is manufactured by Merck & Co., based in Whitehouse Station, N.J.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about shingles.

Copyright © 2011 HealthDay. All rights reserved.

Powered by

Featured Jobs



Benefits of Membership

FREE E-Newsletters
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues

CESaver
Join our CESaver program to earn up to 100 contact hours for only $34.95
Register Now

Lippincott's NursingCenter.com
Explore a world of online resources

Become a Member